Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Taniborbactam

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Venatorx and Melinta Provide Update on Status of NDA for Cefepime-Taniborbactam
    Venatorx and Melinta Provide Update on Status of NDA for Cefepime-Taniborbactam

    23 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240223169844/en

    BUSINESSWIRE
    23 Feb 2024
    Share Share
    New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3
    New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3

    20 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240220917017/en

    BUSINESSWIRE
    20 Feb 2024
    Share Share
    Venatorx and Menarini Enter Agreement for Cefepime-Taniborbactam
    Venatorx and Menarini Enter Agreement for Cefepime-Taniborbactam

    09 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240109280483/en

    BUSINESSWIRE
    09 Jan 2024
    Share Share
    Everest Announces NMPA Recommends Priority Review for Cefepime-Taniborbactam
    Everest Announces NMPA Recommends Priority Review for Cefepime-Taniborbactam

    19 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/everest-medicines-announces-china-center-for-drug-evaluation-of-nmpa-recommends-priority-review-for-cefepime-taniborbactam-for-the-treatment-of-complicated-urinary-tract-infections-including-pyelonephritis-301932731.html

    PR NEWSWIRE
    19 Sep 2023
    Share Share
    Venatorx Announces FDA Acceptance of NDA for Cefepime-Taniborbactam
    Venatorx Announces FDA Acceptance of NDA for Cefepime-Taniborbactam

    15 Aug 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230815163087/en

    BUSINESSWIRE
    15 Aug 2023
    Share Share
    Venatorx Receives FDA Acceptance of NDA for Cefepime-Taniborbactam
    Venatorx Receives FDA Acceptance of NDA for Cefepime-Taniborbactam

    15 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/everest-medicines-partner-venatorx-receives-fda-acceptance-and-priority-review-of-new-drug-application-for-cefepime-taniborbactam-to-treat-complicated-urinary-tract-infections-cuti-301900949.html

    PR NEWSWIRE
    15 Aug 2023
    Share Share